Mitumomab

Drug Profile

Mitumomab

Alternative Names: Anti-idiotype cancer vaccine - ImClone Systems/Merck KGaA; BEC-2; IMC-BEC2; LuVax; MelVax; Monoclonal antibody BEC-2

Latest Information Update: 13 Jun 2005

Price : $50

At a glance

  • Originator ImClone Systems
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma; Small cell lung cancer

Most Recent Events

  • 13 Jun 2005 Discontinued - Phase-II for Malignant melanoma in USA (unspecified route)
  • 13 Jun 2005 Discontinued - Phase-III for Small cell lung cancer in Australia (unspecified route)
  • 13 Jun 2005 Discontinued - Phase-III for Small cell lung cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top